Grow tumour organoids together with the patient's own immune cells
Lab-grown mini-tumours usually contain only cancer cells. Adding the patient's own immune cells lets researchers test immunotherapy outside the body.
Air-liquid interface organoids and reconstituted co-cultures preserve or restore tumour-infiltrating lymphocytes and myeloid cells, and have been used to model checkpoint blockade responses and to expand tumour-reactive T cells. Standardising these systems, including autologous peripheral blood mononuclear cell co-cultures with defined killing readouts, would give an ex vivo assay for immunotherapy and cell therapy that plain organoids cannot provide.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
- No one can predict who responds to immunotherapy · Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating.
Pages like this
not linked directly; found by shared links- IdeaA bone marrow niche on a chip to study human dormancy
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- InstitutionAtrium Health Wake Forest Baptist Comprehensive Cancer Center
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaStandards for spatial and multiplex tissue biomarkers before they reach the clinic
Shares Tumour-infiltrating lymphocytes (TILs), Hot vs cold tumours, No one can predict who responds to immunotherapy.
- IdeaMap which tumour clones sit next to which immune cells before choosing therapy
Shares Tumour-infiltrating lymphocytes (TILs), Hot vs cold tumours, No one can predict who responds to immunotherapy.
- PersonEmile Voest
Shares Netherlands Cancer Institute (NKI-AvL), Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaUse patient organoids to check a cell therapy will work before infusing it
Shares TIL therapy, Patient-derived organoids, Preclinical models that do not predict people.
- InstitutionUMC Utrecht Cancer Center
Shares Netherlands Cancer Institute (NKI-AvL), Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.